1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Distribution
Shanghai Pharmaceuticals Holding Co., Ltd

Shanghai Pharmaceuticals Holding Co., Ltd

SHPMF
Shanghai Pharmaceuticals Holding Co., LtdUS flagOther OTC
1.46
USD
- -
- -
8.46BMarket Cap
Shanghai Pharmaceuticals Holding Co., Ltd
SHPMF
(Other OTC)

Recent

price

1.46

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
19.43
22.68
25.32
29.09
34.36
39.24
44.91
48.66
56.16
65.83
67.44
75.85
66.49
70.46
74.37
76.29
57.52
Revenue per Share
0.73
0.84
0.76
0.82
0.96
1.07
1.19
1.31
1.37
1.44
1.58
1.79
1.61
1.02
1.23
1.54
1.37
Basic EPS, GAAP
0.82
0.56
0.16
0.03
0.02
-0.14
-0.06
0.24
0.42
1.15
1.35
0.33
0.59
0.61
0.93
1.03
-0.48
Free Cash Flow per Basic Share
0.29
0.32
0.33
0.39
0.47
0.51
0.54
0.65
0.83
0.91
0.85
0.94
0.89
1.08
0.97
0.75
0.42
Dividend per Share
2.76
3.26
3.5
4.06
4.72
5.45
6.26
7.17
7.83
8.76
9.8
11.05
10.37
10.16
10.88
11.95
12.29
Book Value per Share
5.78
8.97
8.6
8.86
9.21
10.04
10.49
11.29
10.87
12.16
13.35
14.59
17.22
16.94
18.04
18.37
18.78
Tangible Book Value per Share
1,993
2,421
2,689
2,689
2,689
2,689
2,689
2,689
2,833
2,834
2,846
2,846
3,489
3,694
3,701
3,717
3,731
Basic Weighted Avg Shares
38,722
54,900
68,078
78,223
92,399
105,517
120,765
130,847
159,084
186,566
191,909
215,824
231,981
260,295
275,251
283,580
214,599
Sales/Revenue/Turnover
5.24
4.43
3.92
3.71
3.67
3.75
3.53
3.8
3.92
4.25
4.24
3.67
3.79
3.67
3.52
3.27
3.48
Operating Margin (%)
398
479
537
550
585
673
746
840
1,169
1,885
2,138
2,140
2,222
2,187
2,419
2,862
- -
Depreciation Expense
1,456
2,042
2,053
2,214
2,591
2,877
3,196
3,521
3,881
4,081
4,496
5,093
5,617
3,768
4,553
5,725
5,121
Net Income, GAAP
18.21
19.41
20.31
19.48
21.26
19.36
17.45
22.04
16.6
22.86
21.88
22.95
20.62
26.76
26.81
28.98
28.07
Effective Tax Rate (%)
3.76
3.72
3.02
2.83
2.8
2.73
2.65
2.69
2.44
2.19
2.34
2.36
2.42
1.45
1.65
2.02
2.39
Profit Margin (%)
5,072
15,140
16,704
16,812
16,656
16,159
19,154
19,010
24,568
23,484
19,430
24,670
38,822
40,062
45,785
45,266
46,333
Working Capital
66
52
41
125
105
93
2,836
2,959
9,600
10,290
2,685
8,592
7,561
7,336
9,728
5,385
4,720
LT Debt
12,828
25,981
27,701
29,001
31,099
33,808
36,834
39,676
46,433
49,386
54,741
59,066
78,002
80,326
83,742
89,787
91,468
Total Equity
10.43
7.95
6.68
6.97
7.28
7.67
7.55
7.38
7.78
7.52
7.34
9.71
9.07
5.81
5.53
4.85
3.76
Return on Invested Capital (%)
11.06
13.29
11.92
11.56
12.04
10.82
9.7
9.62
8.36
6.87
6.59
7.16
7.04
4.15
4.68
5.36
4.71
Return on Capital (%)
35.26
30.5
23.74
21.79
21.95
21.04
20.31
19.51
18.73
17.37
17.06
17.17
16.61
10.22
11.71
13.52
11.71
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
46,901
48,871
LT Borrowings
- -
4,236
3,257
LT Finance Leases
- -
1,149
1,463
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
3,708
3,708
Market Capitalization
40,344
37,817
37,585

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
- -
180,464
182,841
Cash, Cash Equivalents & STI
- -
43,083
41,117
Accounts Receivable, Net
- -
82,306
91,150
Inventories
- -
45,359
41,682
Total Current Liabilities
- -
135,198
136,509
Payables & Accruals
- -
- -
- -
ST Debt
- -
46,901
48,871
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.53%
10.88%
7.22%
Free Cash Flow
-13.17%
23.22%
11.73%
Net Income, GAAP
8.4%
7.44%
25.74%
Sales/Revenue/Turnover
10.54%
8.19%
3.03%
Total Cash Common Dividend
8.71%
4.63%
-22.3%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
70,153
69,260
70,216
65,622
275,251
2025
70,763
70,830
- -
68,507
283,580
2026
75,262
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.42
- -
- -
- -
1.23
2025
0.36
- -
- -
- -
1.54
2026
0.38
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.15
- -
- -
- -
0.97
2025
0.11
- -
- -
- -
0.75
2026
0.18
- -
- -
- -
- -
Similar Companies
AmerisourceBergen Corporation (ABC)
Achyut Healthcare Ltd. (ACHYUT.BO)
Tai United Holdings Limited (0718.HK)
McKesson Corporation (MCK)
China National Accord Medicines Corporation Ltd. (000028.SZ)
DocMorris AG (DOCM.SW)
Business
Shanghai Pharmaceuticals Holding Co., Ltd. researches, develops, manufactures, distributes and retails pharmaceutical and healthcare products primarily in China with international operations. The company operates through four main segments: Production, which encompasses research, development and manufacturing of chemical drugs, biological drugs, traditional Chinese medicines, biochemical drugs, healthcare products and medical devices targeting therapeutic areas including cardiovascular, digestive tract and metabolism, anti-infection, central nervous system, anti-tumor and immunomodulators, musculoskeletal and respiratory systems; Distribution, providing pharmaceutical supply chain solutions, logistics, warehousing and related services to manufacturers, hospitals, distributors and retail pharmacies; Retail, managing a network of chain drugstores and online drug sales; and Others, including equity investments and additional healthcare services. It offers approximately 700 varieties of drugs, with certain products achieving sales exceeding RMB 100 million annually and certifications from WHO, FDA and EU standards. Founded in 1994 and headquartered at Shanghai Pharmaceutical Building, No. 200 Taicang Road, Shanghai, China, with registered address at No. 92 Zhangjiang Road, Pilot Free Trade Zone, China (Shanghai), the company trades under tickers 601607.SH on the Shanghai Stock Exchange and 2607.HK on the Hong Kong Stock Exchange, as well as SHPMF over-the-counter. Recent developments include participation as a limited partner with a RMB 1 billion contribution to the establishment of the Shanghai Biomedical M&A Private Equity Fund Partnership in March 2025, totaling RMB 4.66 billion in commitments with partners such as Xinhua Insurance and Tofflon to support pharmaceutical mergers and acquisitions; agreement in early 2025 alongside GP Health Service Capital Co., Ltd. to acquire a 45% equity stake in Shanghai Hutchison Pharmaceuticals Limited from HUTCHMED for approximately USD 608 million to expand oncology and innovative drug capabilities; and a proposed share transfer agreement announced on July 25, 2025, advancing strategic consolidation in pharmaceutical manufacturing and distribution.

Company News

APIChatGPT

  • defenseworld.net

    Shanghai Pharmaceuticals Holding Co., Ltd (OTCMKTS:SHPMF) Short Interest Update